NASDAQ:GHDX Genomic Health (GHDX) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free GHDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$63.44▼$63.4450-Day Range$63.44▼$69.7952-Week Range$50.77▼$90.18VolumeN/AAverage Volume1.05 million shsMarket Capitalization$2.38 billionP/E Ratio60.42Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Genomic Health alerts: Email Address Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Genomic Health Stock (NASDAQ:GHDX)Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.Read More Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency GHDX Stock News HeadlinesMarch 14, 2024 | businesswire.comFabric Genomics Partners with Intermountain Children’s Health to Enhance Precision Diagnosis of Infants and Children Using Whole Genome Sequencing from Broad Clinical LabsFebruary 25, 2024 | msn.comExtreme environments are coded into the genomes of the organisms that live there, research suggestsMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.January 25, 2024 | finance.yahoo.comLondon North West University Healthcare NHS Trust Finds Digital Way Forward with PhenoTips' Genomic Health RecordJanuary 23, 2024 | msn.comNIH grant funds the development of allograft-rejection-on-a-chip modelJanuary 10, 2024 | msn.comNew genomic tests can lead to better cancer careJanuary 8, 2024 | msn.comAI & Genetic Data Integration to Unlock Population Health InsightsJanuary 8, 2024 | markets.businessinsider.comGuardant Health, Hikma To Offer Cancer Screening & Genomic Profiling Tests In Middle East & AfricaMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.November 30, 2023 | sfgate.comFormerly known as Sema4, Stamford-based firm GeneDx cuts 10 percent of workforceNovember 28, 2023 | benzinga.comGenomic Data Revolutionizes GCC Healthcare MarketNovember 1, 2023 | markets.businessinsider.comGeneial Receives New NIH Grant For Private Pharmacogenomics WorkflowOctober 5, 2023 | benzinga.comIntellxxDNA™ Powers Groundbreaking Child Health Study Alongside Documenting Hope™July 12, 2023 | bbc.co.ukGenomic sequencingMay 9, 2023 | omaha.comShould All U.S. Newborns Undergo Genomic Testing?May 9, 2023 | omaha.comPopulation Genomic Screening for Three Conditions Likely Cost-EffectiveMay 5, 2023 | marketwatch.comGenomic Biomarkers Market: Recent Growing Trend 2030April 27, 2023 | benzinga.comGenomics Market worth $83.1 billion | MarketsandMarketsFebruary 22, 2023 | finance.yahoo.comVieCure and Labcorp Collaboration Will Improve Clinical Workflow, Increasing Patient Access to Genomic TestingFebruary 19, 2023 | news.yahoo.comGenomic medicine offers diagnostic hope for people with rare diseases | Pediatric ResearchJanuary 28, 2023 | benzinga.comGeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct OfferingJanuary 26, 2023 | msn.comOpGen gets Chinese patent for detecting genomic variants of drug resistant bacteriaJanuary 6, 2023 | msn.comQiagen, Helix partner to advance NGS companion diagnostics in hereditary diseasesDecember 13, 2022 | forbes.comNHS England Completes Move Towards Rapid Whole Genome Sequencing Of All Critically Ill InfantsSeptember 27, 2022 | markets.businessinsider.comOmica.bio and GenoBank.io Partner to Drive Transparency in Genomic Research in Latin AmericaAugust 20, 2022 | marketwatch.comLuteinizing Hormone Releasing Hormone (LHRH) Agonists Market: Size Analysis By Growth, Trends, and Analysis By 2029August 1, 2022 | benzinga.comEpigenetics Market Size is projected to reach USD 11.83 billion by 2030, growing at a CAGR of 17.05%: Straits ResearchSee More Headlines Receive GHDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genomic Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2019Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:GHDX CUSIP37244C10 CIK1131324 Webwww.genomichealth.com Phone650-556-9300FaxN/AEmployees829Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.05 Trailing P/E Ratio60.42 Forward P/E Ratio40.15 P/E GrowthN/ANet Income$25.68 million Net Margins12.81% Pretax MarginN/A Return on Equity19.62% Return on Assets14.89% Debt Debt-to-Equity Ratio0.15 Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$394.11 million Price / Sales6.05 Cash Flow$1.45 per share Price / Cash Flow43.76 Book Value$7.48 per share Price / Book8.48Miscellaneous Outstanding Shares37,590,000Free FloatN/AMarket Cap$2.38 billion OptionableOptionable Beta0.90 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Kimberly J. Popovits (Age 60)Chairman, CEO & Pres Dr. Steven Shak (Age 68)Co-Founder & Chief Scientific Officer Mr. G. Bradley Cole (Age 63)Chief Financial Officer Dr. Frederic G. Pla (Age 60)Chief Operating Officer Mr. James J. Vaughn (Age 56)Chief U.S. Commercial Officer Key CompetitorsGuardant HealthNASDAQ:GHVeracyteNASDAQ:VCYTRadNetNASDAQ:RDNTFortreaNASDAQ:FTREViridian TherapeuticsNASDAQ:VRDNView All Competitors GHDX Stock Analysis - Frequently Asked Questions How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) issued its earnings results on Monday, November, 11th. The medical research company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.11. Genomic Health had a trailing twelve-month return on equity of 19.62% and a net margin of 12.81%. What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include Horizon Therapeutics Public (HZNP), Revance Therapeutics (RVNC), Exelixis (EXEL), Gilead Sciences (GILD), Illumina (ILMN), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (bmrn) and GW Pharmaceuticals (GWPH). This page (NASDAQ:GHDX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genomic Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.